Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

Merck is taking steps to suspend the availability of its cholesterol drug, Tredaptive tablets worldwide, following a recommendation from European regulators. Tredaptive (extended-release niacin ...

These drugs include treatments for rare diseases, hepatitis C and cancer, such as Merck's own Keytruda ... profile example concerned the new high cholesterol treatments, Sanofi's Praluent and ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

In pulmonology, all eyes are on Merck’s sotatercept and its early 2025 earnings results in pulmonary arterial hypertension — set to speak to ultra-high expectations for the potentially “game-changing” ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its covid antibody cocktail as ...

Within the Sanofi antibody collaboration, LDL cholesterol reduction drug Praluent has seen a slow ... Roy Vagelos, the former CEO of Merck, since 1995, and despite his recent retirement, the ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

or high cholesterol. However, it too was quickly being prescribed off-label for general weight-loss purposes. The drug soared out of the gate to become Eli Lily's fourth-best-selling drug in the ...

They could partially offset these losses, i.e., Repatha, the cholesterol lowerer ... portfolio could be bolstered by biosimilar drugs for Merck's and Bristol Myers Squibb's cancer “mega ...